Evidence map›Paper›PMID 42423939›Full record

ArticleAnnals of surgical oncology2026

Outcomes of Neoadjuvant Radiotherapy Followed by Robotic Radical Prostatectomy in High-Risk Locally Advanced Prostate Cancer: A Prospective Pilot Study.

Chi-Shin Tseng, Chih-Kai Chang, Hsing-Ju Li, Yen-Ting Liu, Shi-Wei Huang, Chao-Yuan Huang, Jason Chia-Hsien Cheng

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chi-Shin TsengGraduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
Chih-Kai ChangDepartment of Medical Imaging, National Taiwan University Hospital, National Taiwan University, Taipei, Taiwan.
Hsing-Ju LiDivision of Radiation Oncology, Department of Oncology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Yen-Ting LiuDepartment of Biomedical Engineering, National Taiwan University, Taipei, Taiwan.
Shi-Wei HuangDepartment of Urology, National Taiwan University Hospital Yunlin Branch, Yunlin County, Taiwan.
Chao-Yuan HuangDepartment of Urology, National Taiwan University Hospital, National Taiwan University, Taipei, Taiwan. cyh540909@gmail.com.
Jason Chia-Hsien ChengGraduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan. jasoncheng@ntu.edu.tw.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeNeoadjuvant radiotherapy (RT) in prostate cancer remains investigational. This prospective pilot study evaluated the feasibility, perioperative safety, and preliminary outcomes of neoadjuvant RT combined with androgen-deprivation therapy (ADT), followed by robot-assisted radical prostatectomy (RP), in high-risk locally advanced disease.

methodsPatients with high-risk locally advanced prostate cancer (clinical stage T3a-T3b, Gleason score ≥8, or prostate-specific antigen [PSA] ≥ 20 ng/mL) were prospectively enrolled. All patients received neoadjuvant RT (50 Gy in 25 fractions) with 3 months of ADT, then robot-assisted RP with pelvic lymph node dissection. A retrospective contemporaneous RP-alone cohort served as controls. Primary outcomes included perioperative safety, pathological response, and postoperative PSA levels. Secondary endpoints included oncological outcomes, functional outcomes, and MRI-derived imaging biomarkers.

resultsIn total, 10 patients received neoadjuvant RT, and 11 patients served as controls. The median PSA at diagnosis was 19.46 ng/mL in the neoadjuvant group and 15.52 ng/mL in controls. No major complications occurred. Pathological downstaging was observed in 60% of the neoadjuvant group, whereas none occurred in controls (4/11 showed upstaging). At 12 months, urinary continence was achieved in four patients. After a median follow-up of 16.4 months, five patients developed biochemical recurrence, and one progressed to bone metastasis. Post-treatment changes in apparent diffusion coefficient values and T2-weighted MRI signals were associated with improved pathological outcomes, suggesting potential predictive value.

conclusionsNeoadjuvant RT with ADT followed by RP is feasible and well tolerated in high-risk locally advanced prostate cancer. Although pathological downstaging was observed, this pilot study does not support definitive conclusions regarding oncologic benefit, and larger prospective studies are warranted.

Indexed as

Neoadjuvant TherapyProstatectomyProstatic NeoplasmsRobotic Surgical ProceduresAgedAndrogen AntagonistsCombined Modality TherapyFeasibility StudiesFollow-Up StudiesHumansLymph Node ExcisionMaleMiddle AgedNeoplasm StagingPilot ProjectsPrognosisAndrogen AntagonistsProstate-Specific AntigenHormone therapyNeoadjuvantProstate cancerProstatectomyRadiotherapy

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.